Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species
- PMID: 6725557
- PMCID: PMC437085
- DOI: 10.1172/JCI111381
Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species
Abstract
A single-chain 55,000-mol wt form of urokinase (UK), similar to that previously isolated from urine, was purified from a transformed kidney cell culture medium and characterized; and its fibrinolytic properties were evaluated. The preparation immunoprecipitated with UK antiserum, had a low intrinsic amidolytic activity that was 0.1% of its active derivative, and resisted diisopropyl fluorophosphate treatment and inactivation by plasma inhibitors. The single-chain UK was therefore designated pro-UK. In the presence of plasmin and during clot lysis, activation by conversion to two-chain, 55,000-mol wt UK (TC-UK) was demonstrated. This did not occur during blood clotting nor on incubation with purified thrombin. Clot lysis in plasma consistently occurred in 2-5 h with 50-100 IU per ml of pro-UK, whereas comparable lysis was inconsistently achieved by 500-1,000 IU of UK. Pro-UK, in sharp contrast to UK, caused no fibrinogen degradation at fibrinolytic concentrations. In the absence of a clot, pro-UK in plasma was stable for more than 2 d. When a clot was added after incubation (37 degrees C) for 50 h, activation to full lytic activity took place. The findings in vivo were comparable but the rapid clearance of pro-UK required that it be given by a constant infusion despite its plasma stability. In rabbits, a UK-resistant species, pro-UK was significantly (P less than 0.001) more efficacious than TC-UK but neither induced significant fibrinogen degradation. In dogs, a more sensitive species, the high specificity of thrombolysis by pro-UK contrasted with the defibrinogenation and uncontrollable bleeding that accompanied thrombolysis by UK. It was concluded that clot lysis by pro-UK is more effective and specific than UK. The advantage of pro-UK is in the limitation of its activation to the site of a clot. This can be explained by an activation mechanism that is dependent, under physiological conditions, on fibrin-stabilized plasmin.
Similar articles
-
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.Thromb Haemost. 1984 Aug 31;52(1):31-3. Thromb Haemost. 1984. PMID: 6495261
-
Transport of urokinase across the intestinal tract of normal human subjects with stimulation of synthesis and/or release of urokinase-type proteins.J Clin Invest. 1985 Apr;75(4):1212-22. doi: 10.1172/JCI111818. J Clin Invest. 1985. PMID: 3921568 Free PMC article.
-
Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.Blood. 1986 May;67(5):1215-23. Blood. 1986. PMID: 3083889
-
New approaches to thrombolytic therapy.Arteriosclerosis. 1984 Nov-Dec;4(6):579-85. doi: 10.1161/01.atv.4.6.579. Arteriosclerosis. 1984. PMID: 6439177 Review.
-
Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.J Cell Biochem. 1987 Feb;33(2):77-86. doi: 10.1002/jcb.240330202. J Cell Biochem. 1987. PMID: 3553213 Review.
Cited by
-
Centrifugal and roller pumps--are there differences in coagulation and fibrinolysis during and after cardiopulmonary bypass?Heart Vessels. 1995;10(1):46-53. doi: 10.1007/BF01745077. Heart Vessels. 1995. PMID: 7730247 Clinical Trial.
-
Inactivation of human tumor cell pro-urokinase by granulocyte elastase.Jpn J Cancer Res. 1990 Oct;81(10):994-1002. doi: 10.1111/j.1349-7006.1990.tb03337.x. Jpn J Cancer Res. 1990. PMID: 2121685 Free PMC article.
-
Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.J Clin Invest. 1988 Mar;81(3):853-9. doi: 10.1172/JCI113394. J Clin Invest. 1988. PMID: 2963831 Free PMC article.
-
[Significance of the endothelium of the vascular wall for maintaining hemostasis].Klin Wochenschr. 1985 Dec 16;63(24):1237-46. doi: 10.1007/BF01738448. Klin Wochenschr. 1985. PMID: 3003450 German.
-
Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration.J Thromb Thrombolysis. 1999 Oct;8(3):213-21. doi: 10.1023/a:1008914321384. J Thromb Thrombolysis. 1999. PMID: 10500311 Clinical Trial.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources